The abstract is read at the publisher; the summary is JClub's.
Dragonfly point-of-care testing for MPXV and OPXV in Kampala and Wakiso, Uganda, matched qPCR with 98·7% overall agreement and results in under 40 minutes.
- Why it matters: Centralized qPCR for mpox needs specialized infrastructure and transport, creating turnaround delays that hinder public health action, especially in remote or underserved settings.
- What they did: In a prospective diagnostic accuracy study across six facilities, lesion swabs from 300 consecutively enrolled suspected mpox patients were tested with Dragonfly (dual-target OPXV/MPXV) and then confirmed by qPCR.
- The result: Dragonfly sensitivity for MPXV was 98·5% and specificity 96·2%, with OPXV sensitivity 100% and specificity 96·2%, and front-line users reported high acceptability despite training and supply-chain needs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.